LONDON (Reuters) - Europe's drug regulator said on Friday it had recommended the suspension of a number of drugs which were approved on the basis of clinical studies conducted at GVK Biosciences in Hyderabad, India.
The European Medicines Agency said the recommendation was based on findings from an inspection that raised concerns about how GVK conducted studies at the Hyderabad site on behalf of the pharmaceutical companies.
The move follows a similar decision from state regulators in France, Germany, Belgium and Luxembourg in December to suspend the marketing approval of 25 generic drugs due to concerns over the quality of data from clinical trials conducted by the Indian firm.
(Reporting by Kate Holton; editing by Paul Sandle)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app